Decreased Periprosthetic Bone Loss in Patients Treated with Clodronate: A 1-Year Randomized Controlled Study

• Published in: Calcified tissue international 2010-06, Vol.86 (6), p.436-446
• Main Authors: Trevisan, C., Ortolani, S., Romano, P., Isaia, G., Agnese, L., Dallari, D., Grappiolo, G., Cherubini, R., Massari, L., Bianchi, G.
• Format: Article
• Language: English
• Subjects: Absorptiometry, Photon; Aged; Arthroplasty, Replacement, Hip - adverse effects; Biochemistry; Biomedical and Life Sciences; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; Bone Resorption - prevention & control; Cell Biology; Clinical outcomes; Clodronic Acid - therapeutic use; Drug therapy; Endocrinology; Female; Hip joint; Humans; Joint surgery; Life Sciences; Male; Middle Aged; Orthopedics; Osteoporosis
• ISSN: 0171-967X; 1432-0827
• DOI: 10.1007/s00223-010-9356-1

The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance ( P   0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.